Dr. David Kideckel
Managing Director, Senior Equity Research Analyst, Healthcare & Life Sciences, AltaCorp Capital
Dr. David Kideckel is Managing Director, Senior Equity Research Analyst, Healthcare & Life Sciences at AltaCorp Capital. Previously, David was at another leading Canadian independent investment dealer, where he led the cannabis franchise to new heights in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. He was the only analyst in Canada to cover Nasdaq-listed and world-leader in cannabinoid-derived pharmaceuticals, GW Pharma. Prior to that, David held executive positions at various international pharmaceutical and medical device companies, including the global leader in rare diseases and Nasdaq-Listed, Alexion Pharmaceuticals, OtoSim Inc. and Johnson & Johnson.
A native Winnipegger, David graduated from the University of Winnipeg with a Bachelor of Science and Bachelor of Arts in Neuropsychology. He has also earned a Master of Science from McMaster University, as well as a PhD from the Institute of Medical Science & Program in Neuroscience at the University of Toronto and as well as a Master of Business Administration from the Rotman School of Management.